Brief: Transgene Says Tg4001 Phase II Study Fails To Meet Primary Objective
14/10/2024 06:32
Oct 14 (Reuters) - Transgene SA TRNG.PA :
* TRANSGENE PROVIDES UPDATE ON PHASE II TRIAL OF THERAPEUTIC
CANCER VACCINE TG4001 IN RECURRENT OR METASTATIC HPV16-POSITIVE
CERVICAL AND ANOGENITAL CANCERS
* TRANSGENE SA - TG4001 PHASE II STUDY FAILS TO MEET PRIMARY
OBJECTIVE
Source text for Eikon: ID:nGNX9Y8QB9
Further company coverage: TRNG.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transgene SA
See all newsFrance's Transgene H1 operating income falls on lower tax credit
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs